The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Coronary Stent Restenosis in Patients Treated With Cilostazol
Abstract
Background— Restenosis after implantation of coronary artery stents remains a significant clinical problem. We undertook a randomized, double-blind, placebo-controlled trial to determine whether cilostazol, a drug that suppresses intimal proliferation, would reduce renarrowing in patients after stent implantation in native coronary arteries. Methods and Results— We assigned 705 patients who had successful coronary stent implantation to receive, in addition to aspirin, cilostazol 100 mg BID or placebo for 6 months; clopidogrel 75 mg daily was administered to all patients for 30 days. Restenosis was determined by quantitative coronary angiography at 6 months. The minimal luminal diameter at 6 months for cilostazol-treated patients was 1.77 mm for the analysis segment (stent plus 5-mm borders) compared with 1.62 mm in the placebo group ( P =0.01). Restenosis, defined as ≥50% narrowing, occurred in 22.0% of patients in the cilostazol group and in 34.5% of the placebo group ( P =0.002), a 36% relative risk reduction. Restenosis was significantly lower in cilostazol-treated diabetics (17.7% versus 37.7%, P =0.01) and in those with small vessels (23.6% versus 35.2%, P =0.02), long lesions (29.9% versus 46.6%, P =0.04), and left anterior descending coronary artery site (19.3% versus 39.8%, P =0.001). There was no difference in bleeding, rehospitalization, target-vessel revascularization, myocardial infarction, or death. Conclusions— Treatment with the drug cilostazol resulted in a significantly larger minimal luminal diameter and a significantly lower binary restenosis rate compared with placebo-treated patients. These favorable effects were apparent in patients at high risk for restenosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Serruys, P. W., de Jaegere, P., Kiemeneij, F., Macaya, C., Rutsch, W., Heyndrickx, G., Emanuelsson, H., Marco, J., Legrand, V., Materne, P., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199408253310801 · Cited by 4,556
Fischman, D. L., Leon, M. B., Baim, D. S., Schatz, R. A., Savage, M. P., Penn, I., Detre, K., Veltri, L., Ricci, D., Nobuyoshi, M., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199408253310802 · Cited by 4,271
Moses, J. W., Leon, M. B., Popma, J. J., Fitzgerald, P. J., Holmes, D. R., O'Shaughnessy, C., Caputo, R. P., Kereiakes, D. J., Williams, D. O., Teirstein, P. S., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035071 · Cited by 4,224
Self-citationA Polymer-Based, Paclitaxel-Eluting Stent in Patients with Coronary Artery Disease
Stone, G. W., Ellis, S. G., Cox, D. A., Hermiller, J., O'Shaughnessy, C., Mann, J. T., Turco, M., Caputo, R., Bergin, P., Greenberg, J., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032441 · Cited by 2,749
Virmani, R., Guagliumi, G., Farb, A., Musumeci, G., Grieco, N., Motta, T., Mihalcsik, L., Tespili, M., Valsecchi, O., & Kolodgie, F. D. (2004) · Circulation · doi:10.1161/01.cir.0000116202.41966.d4 · Cited by 1,469
Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy
McFadden, E. P., Stabile, E., Regar, E., Cheneau, E., Ong, A. T., Kinnaird, T., Suddath, W. O., Weissman, N. J., Torguson, R., Kent, K. M., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17275-9 · Cited by 1,436
Predictive Factors of Restenosis After Coronary Stent Placement
Kastrati, A., Schömig, A., Elezi, S., Schühlen, H., Dirschinger, J., Hadamitzky, M., Wehinger, A., Hausleiter, J., Walter, H., & Neumann, F.-J. (1997) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(97)00334-3 · Cited by 685
A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents
Babapulle, M. N., Joseph, L., Bélisle, P., Brophy, J. M., & Eisenberg, M. J. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16850-5 · Cited by 645
Clinical restenosis after coronary stenting: perspectives from multicenter clinical trials
Cutlip, D. E., Chauhan, M. S., Baim, D. S., Ho, K. K. L., Popma, J. J., Carrozza, J. P., Cohen, D. J., & Kuntz, R. E. (2002) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)02597-4 · Cited by 423
Folate Therapy and In-Stent Restenosis after Coronary Stenting
Lange, H., Suryapranata, H., De Luca, G., Börner, C., Dille, J., Kallmayer, K., Pasalary, M. N., Scherer, E., & Dambrink, J.-H. E. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032845 · Cited by 336
Cited by
The Perioperative Management of Antithrombotic Therapy
Douketis, J. D., Berger, P. B., Dunn, A. S., Jaffer, A. K., Spyropoulos, A. C., Becker, R. C., & Ansell, J. (2008) · Chest · doi:10.1378/chest.08-0675 · Cited by 830
Advances in targeting cyclic nucleotide phosphodiesterases
Maurice, D. H., Ke, H., Ahmad, F., Wang, Y., Chung, J., & Manganiello, V. C. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4228 · Cited by 776
Anti-inflammatory therapies for atherosclerosis
Bäck, M., & Hansson, G. K. (2015) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2015.5 · Cited by 378
Clinical Aspects of Platelet Inhibitors and Thrombus Formation
Meadows, T. A., & Bhatt, D. L. (2007) · Circulation Research · doi:10.1161/01.res.0000264509.36234.51 · Cited by 351
Diabetes and Antiplatelet Therapy in Acute Coronary Syndrome
Ferreiro, J. L., & Angiolillo, D. J. (2011) · Circulation · doi:10.1161/circulationaha.109.913376 · Cited by 333
Metadata
- Authors
- Douglas, J. S., Holmes, D. R., Kereiakes, D. J., Grines, C. L., Block, E., Ghazzal, Z. M. B., Morris, D. C., Liberman, H., Parker, K., Jurkovitz, C., Murrah, N., Foster, J., Hyde, P., Mancini, G. B. J., & Weintraub, W. S.
- Venue
- Circulation
- Published
- 2005-11
- Volume
- 112
- Issue
- 18
- Pages
- 2826-2832
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2119380659
- Cited by
- 281
- References
- 15
- FWCI
- 16.77
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Coronary Stent Restenosis in Patients Treated With Cilostazol. https://app.cochat.ai/papers/10.1161/circulationaha.104.530097
- The paper
- Douglas, J. S., Holmes, D. R., Kereiakes, D. J., Grines, C. L., Block, E., Ghazzal, Z. M. B., Morris, D. C., Liberman, H., Parker, K., Jurkovitz, C., Murrah, N., Foster, J., Hyde, P., Mancini, G. B. J., & Weintraub, W. S. (2005). Coronary Stent Restenosis in Patients Treated With Cilostazol. Circulation. https://doi.org/10.1161/circulationaha.104.530097
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.